A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a Phase 2 study to evaluate the clinical activity, safety, pharmacokinetics (PK), and related biomarkers of ZN-c3 in adult women with recurrent or persistent uterine serous carcinoma (USC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: K-Group Beta

Criteria

Inclusion Criteria:

• Females age ≥18 years of age at the time of informed consent.

• Recurrent or persistent USC.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

• Measurable disease, defined as at least one lesion that can be accurately measured per revised Response Evaluation Criteria in Solid Tumors RECIST Guideline version 1.1 criteria.

• Adequate hematologic and organ function.

• Females of childbearing potential must agree to use an effective method of contraception per institutional standard prior to the first dose and for 90 days after the last dose of ZN c3.

Exclusion Criteria:

• Prior treatment with a cell cycle checkpoint inhibitor.

• Prior therapy with ZN-c3 or any other WEE1 inhibitor.

• A serious illness or medical condition(s).

• Unresolved toxicity of Grade > 1 attributed to any prior therapies (excluding ≤Grade 2 neuropathy, alopecia, or skin pigmentation).

• Pregnant or lactating females (including the cessation of lactation) or females of childbearing potential who have a positive serum pregnancy test within 28 days prior to C1D1.

• Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.

• 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of > 480 ms at screening, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.

• History or current evidence of congenital or family history of long QT syndrome.